AIベース臨床試験ソリューションプロバイダーの市場規模、シェア、動向分析レポート：治療用途別、臨床試験フェーズ別、最終用途別、地域別、セグメント別予測、2024年～2030年

AIベース臨床試験ソリューションプロバイダー市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、AIベース臨床試験ソリューションプロバイダーの世界市場規模は、予測期間中にCAGR 22.1％を記録し、2030年までに78億米ドルに達すると予測されています。

AIは汎用性の高いツールであり、薬剤研究の運用効果を向上させ、創薬プロセスを加速させるために活用されるようになってきています。また、医薬品開発プロセスのコストを最小化するためにも大いに採用されています。様々な学界や製薬会社がAIベースのプラットフォームや技術を積極的に採用しています。例えば、2020年1月、バイエルは英国に拠点を置くAI主導の創薬企業とパートナーシップを締結し、AI創薬プラットフォームを用いた初期研究プロジェクトに取り組んでいます。さらに、研究開発を後押しする官民の取り組みと、薬剤研究の分野でAIが提供する多様な応用が、成長を後押ししています。

臨床試験のフェーズに基づくと、創薬件数の増加や第2フェーズでアクティブな試験の数が多いことから、フェーズIIが2023年に45.5%のシェアを獲得して市場を独占しました。さらに、このフェーズでの臨床試験を通じて、データの収集と全体的な望ましい結果の即時分析のためのAIベースのツールの採用が増加していることが、このセグメントの成長に寄与しています。さらに、AIベースのツールに関する施策の改善、決定、検証はこのフェーズで実施できるため、このセグメントはより高い収益シェアを保持しています。

2023年、AIベース臨床試験ソリューションプロバイダー市場において、治療用途に基づくと、腫瘍学が最も高い収益シェアを占めています。世界中でがんの有病率が増加し、腫瘍学分野における薬剤研究の数が増加していることが、AIを可能にする技術の採用に寄与しています。また、先進的な腫瘍学ベースのAIツールを開発し、薬剤研究に採用するプレーヤーが増えており、それによってこのセグメントの成長を促進しています。

2023年には、製薬企業が最終用途に基づく市場で最も高い収益シェアを占めました。大手製薬企業による新薬ターゲットの同定、新薬開発および新薬試験の全体的なプロセス、診断およびバイオマーカーのより良い開発のためのAIベースの技術の採用の高まりは、セグメント成長の主な要因の1つです。さらに、これらの大手製薬企業は、研究開発および創薬プロセス全体にAI技術を活用するためにAIベンダーと協力しており、それが成長を後押ししています。

北米が市場を独占し、2023年の収益シェアは43.4%でした。この優位性は、同地域で新興企業の数が増加していることに起因しています。例えば、Bullfrog AIは米国を拠点とする新興企業で、精密医療を可能にする独自のAIプラットフォームbfLEAPを開発しています。また、AIベースの技術に対する認識の高まりと、薬剤研究の成果を高めるための採用が、同地域の市場成長を後押ししています。さらに、政府の支援策や大手企業による戦略的イニシアチブの増加が、同地域におけるAIベースの臨床試験ソリューションの需要を促進しています。

AIベースの技術は、COVID-19の発生によりその採用が急増しました。このように、医薬品開発およびリクルートされた患者のデータ分析のために技術的に高度なソリューションの採用が増加していることが、AI対応ソリューションの採用急増に寄与しています。さらに、パンデミックの間、多くの医薬品開発プロセスが保留されました。そのため、市場の多くの主要企業がAIベースのソリューションの活用に重点を移し、それによって分散型治験が後押しされました。さらに、これらのソリューションを通じて大量の患者データを効果的に分析することが、市場の成長を支えました。

AIベース臨床試験ソリューションプロバイダー市場レポートハイライト

• 第II相臨床試験セグメントが2023年の市場を独占しました。
• がんの有病率の上昇とがん領域での薬剤研究の増加により、2023年にはがん領域セグメントが市場を独占しました。
• 製薬企業セグメントは、大手製薬企業による医薬品開発のための人工知能技術の採用増加により、市場で最も高い収益シェアを占めました。
• 北米が市場を独占し、2023年には43.4％の収益シェアを占めました。これは、同地域における臨床試験数の増加、人工知能プラットフォームとツールの採用拡大、医薬品開発における人工知能をベースとする新興企業や企業の増加、AIベースのツールや技術に関する意識の高まりなど、さまざまな要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• AIベース臨床試験ソリューションプロバイダー市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響
• ケーススタディ

第4章 AIベース臨床試験ソリューションプロバイダー市場：治療用途の推定・動向分析

• セグメントダッシュボード
• 治療用途の動向と市場シェア分析、2023年と2030年
• 治療用途別AIベース臨床試験ソリューションプロバイダーの世界市場展望
• 腫瘍学
• CVD
• 神経疾患または症状
• 代謝性疾患
• 感染症
• その他

第5章 AIベース臨床試験ソリューションプロバイダー市場：臨床試験フェーズの推定・動向分析

• セグメントダッシュボード
• 臨床試験フェーズの動向と市場シェア分析、2023年と2030年
• 臨床試験フェーズ別AIベース臨床試験ソリューションプロバイダー市場の世界的展望
• フェーズI
• フェーズII
• フェーズIII

第6章 AIベース臨床試験ソリューションプロバイダー市場：最終用途の推定・動向分析

• セグメントダッシュボード
• 最終用途動向と市場シェア分析、2023年と2030年
• 最終用途別AIベース臨床試験ソリューションプロバイダー市場展望
• 製薬会社
• 学術
• その他

第7章 AIベース臨床試験ソリューションプロバイダー市場：地域推定・動向分析、治療用途別、臨床試験段階別、最終用途別

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場のスナップショット
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 主要企業の市場シェア/ポジション分析、2023年
• 企業プロファイル
  • Unlearn.ai, Inc.
  • Saama
  • Antidote Technologies, Inc.
  • Phesi
  • Deep6.ai
  • Innoplexus
  • Mendel Health Inc.
  • Intelligencia AI
  • Median Technologies
  • SymphonyAI
  • BioAge Labs, Inc.
  • AiCure
  • Consilx
  • DeepLens.AI
  • HaloHealth
  • PHARMASEAL
  • Ardigen
  • Trials.ai
  • Koneksa Health
  • Euretos
  • BioSymetrics, Inc.
  • Verily（Google LLC）
  • Aitia
  • IBM
  • Exscientia

List of Tables

• Table 1 List of abbreviation
• Table 2 North America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
• Table 3 North America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 4 North America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 5 North America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 6 U.S. AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 7 U.S. AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 8 U.S. AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 9 Canada AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 10 Canada AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 11 Canada AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 12 Europe AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 14 Europe AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 15 Europe AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 16 Germany AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 17 Germany AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 18 Germany AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 19 UK AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 20 UK AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 21 UK AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 22 France AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 23 France AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 24 France AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 25 Italy AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 26 Italy AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 27 Italy AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 28 Spain AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 29 Spain AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 30 Spain AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 31 Denmark AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 32 Denmark AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 33 Denmark AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 34 Sweden AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 35 Sweden AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 36 Sweden AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 37 Norway AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 38 Norway AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 39 Norway AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 44 China AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 45 China AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 46 China AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 47 Japan AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 48 Japan AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 49 Japan AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 50 India AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 51 India AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 52 India AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 53 South Korea AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 54 South Korea AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 55 South Korea AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 56 Australia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 57 Australia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 58 Australia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 59 Thailand AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 60 Thailand AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 61 Thailand AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 62 Latin America AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
• Table 63 Latin America AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 64 Latin America AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 65 Latin America AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 66 Brazil AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 67 Brazil AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 68 Brazil AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 69 Argentina AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 70 Argentina AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 71 Argentina AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 72 Mexico AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 73 Mexico AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 74 Mexico AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 75 MEA AI-based clinical trials solution providers market, by region, 2018 - 2030 (USD Million)
• Table 76 MEA AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 77 MEA AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 78 MEA AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 79 South Africa AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 80 South Africa AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 81 South Africa AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 85 UAE AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 86 UAE AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 87 UAE AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)
• Table 88 Kuwait AI-based clinical trials solution providers market, by therapeutic applications, 2018 - 2030 (USD Million)
• Table 89 Kuwait AI-based clinical trials solution providers market, by clinical trial phase, 2018 - 2030 (USD Million)
• Table 90 Kuwait AI-based clinical trials solution providers market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 AI-Based Clinical Trials Solution Providers market: market outlook
• Fig. 9 AI-Based Clinical Trials Solution Providers competitive insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 AI-Based Clinical Trials Solution Providers market driver impact
• Fig. 15 AI-Based Clinical Trials Solution Providers market restraint impact
• Fig. 16 AI-Based Clinical Trials Solution Providers market strategic initiatives analysis
• Fig. 17 AI-Based Clinical Trials Solution Providers market: Therapeutic applications movement analysis
• Fig. 18 AI-Based Clinical Trials Solution Providers market: Therapeutic applications outlook and key takeaways
• Fig. 19 Oncology market estimates and forecast, 2018 - 2030
• Fig. 20 CVD market estimates and forecast, 2018 - 2030
• Fig. 21 Neurological diseases or conditions market estimates and forecast, 2018 - 2030
• Fig. 22 Metabolic diseases market estimates and forecast, 2018 - 2030
• Fig. 23 Infectious diseases market estimates and forecast, 2018 - 2030
• Fig. 24 Others market estimates and forecast, 2018 - 2030
• Fig. 25 AI-Based Clinical Trials Solution Providers market: Clinical trial phase analysis
• Fig. 26 AI-Based Clinical Trials Solution Providers market: Clinical trial phase outlook and key takeaways
• Fig. 27 Phase-I market estimates and forecast, 2018 - 2030
• Fig. 28 Phase-II market estimates and forecast, 2018 - 2030
• Fig. 29 Phase-III market estimates and forecast, 2018 - 2030
• Fig. 30 AI-Based Clinical Trials Solution Providers market: End use movement analysis
• Fig. 31 AI-Based Clinical Trials Solution Providers market: End use outlook and key takeaways
• Fig. 32 Pharmaceutical companies market estimates and forecast, 2018 - 2030
• Fig. 33 Academia market estimates and forecast, 2018 - 2030
• Fig. 34 Others market estimates and forecast, 2018 - 2030
• Fig. 35 Global AI-based clinical trials solution providers market: Regional movement analysis
• Fig. 36 Global AI-based clinical trials solution providers market: Regional outlook and key takeaways
• Fig. 37 Global AI-based clinical trials solution providers market share and leading players
• Fig. 38 North America market share and leading players
• Fig. 39 Europe market share and leading players
• Fig. 40 Asia Pacific market share and leading players
• Fig. 41 Latin America market share and leading players
• Fig. 42 Middle East & Africa market share and leading players
• Fig. 43 North America: SWOT
• Fig. 44 Europe SWOT
• Fig. 45 Asia Pacific SWOT
• Fig. 46 Latin America SWOT
• Fig. 47 MEA SWOT
• Fig. 48 North America market estimates and forecasts, 2018 - 2030
• Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 50 Canada market estimates and forecasts, 2018 - 2030
• Fig. 51 Europe market estimates and forecasts, 2018 - 2030
• Fig. 52 UK market estimates and forecasts, 2018 - 2030
• Fig. 53 Germany market estimates and forecasts, 2018 - 2030
• Fig. 54 France market estimates and forecasts, 2018 - 2030
• Fig. 55 Italy market estimates and forecasts, 2018 - 2030
• Fig. 56 Spain market estimates and forecasts, 2018 - 2030
• Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 59 Norway market estimates and forecasts, 2018 - 2030
• Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 61 China market estimates and forecasts, 2018 - 2030
• Fig. 62 Japan market estimates and forecasts, 2018 - 2030
• Fig. 63 India market estimates and forecasts, 2018 - 2030
• Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 66 Australia market estimates and forecasts, 2018 - 2030
• Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 74 UAE market estimates and forecasts, 2018 - 2030
• Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 76 Company Categorization
• Fig. 77 Company market position/share analysis
• Fig. 78 Strategic Framework

AI-based Clinical Trials Solution Provider Market Growth & Trends:

The global AI-based clinical trials solution provider market size is expected to reach USD 7.8 billion by 2030, registering a CAGR of 22.1% during the forecast period, according to a new report by Grand View Research, Inc.. AI is a versatile tool and is being increasingly utilized to improve the operational efficacy of drug studies and accelerate the drug discovery process. Also, it is highly adopted to minimize the cost of the drug development process. Various academia and pharmaceutical companies are actively adopting AI-based platforms and technologies. For instance, in January 2020, Bayer entered into a partnership with an AI-driven drug discovery company based in the UK to work on early research projects using the AI drug discovery platform. Furthermore, the initiatives by the public and private sectors to boost the R&D coupled with the diverse applications provided by AI in the field of drug studies are impelling the growth.

Based on the phase of the clinical trial, Phase II dominated the market with a share of 45.5% in 2023 owing to the rising number of drug discoveries and a large number of studies active in the second phase. Moreover, the increasing adoption of AI-based tools for the collection of data and the analysis of immediate outcomes of the overall desired outcome through the clinical trials in this phase is contributing to the segment growth. Furthermore, the segment holds a higher revenue share as the improvement, determination, and validation of measures with respect to the AI-based tool can be carried out in this phase.

In 2023, based on therapeutic applications, oncology accounted for the highest revenue share in the AI-based clinical trials solution provider market. The increasing prevalence of cancer across the globe and the rising number of drug studies in the field of oncology is contributing to the adoption of AI enables technologies. Also, an increasing number of players are developing and adopting advanced oncology-based AI tools for drug studies, thereby propelling the segment growth.

In 2023, pharmaceutical companies accounted for the highest revenue share in the market, based on end-use. The rising adoption of AI-based technologies for the better development of diagnostic and biomarkers, to identify the new drug target and the overall process of drug development and drug trials by major pharmaceutical players is one of the major factors contributing to the segment growth. Moreover, these major pharmaceutical players are collaborating with the AI vendor for leveraging the AI technology for R&D and the overall drug discovery process, thereby, impelling the growth.

North America dominated the market and accounted for a revenue share of 43.4% in 2023. This dominance is attributed to the rising number of start-ups in the region. For instance, Bullfrog AI is a U.S.-based startup that develops bfLEAP, a proprietary AI platform to enable precision medicine. Also, the growing awareness of AI-based technologies and their adoption to enhance the drug studies' outcomes is impelling the market growth in the region. Furthermore, the supportive government initiatives and increasing strategic initiatives by major players are driving the demand for AI-based clinical trial solutions in the region.

The AI-based technologies witnessed a surge in their adoption due to the outbreak of COVID-19. This increasing adoption of technologically advanced solutions for drug development and for the analyses of the recruited patient's data contributed to the upsurge in the adoption of AI-enabled solutions. Moreover, many drug development processes were on hold during the pandemic. Therefore, many key companies in the market shifted their focus on the utilization of AI-based solutions, thereby boosting decentralized drug trials. Furthermore, the effective analysis of a large amount of patient data through these solutions supported the market growth.

AI-based Clinical Trials Solution Provider Market Report Highlights:

• The phase-II trials segment dominated the market in 2023, owing to the increasing number of active drug studies in this phase
• The oncology segment dominated the market in 2023, owing to the rising prevalence of cancer and the growing number of drug studies in the oncology field
• The pharmaceutical companies segment accounted for the highest revenue share in the market owing to the increasing adoption of artificial intelligence technologies for drug development by major pharmaceutical players
• North America dominated the market and accounted for a revenue share of 43.4% in 2023, owing to various factors including the increasing number of clinical trials in the region, growing adoption of artificial intelligence platforms and tools, rising number of start-ups and companies based on artificial intelligence in drug development and growing awareness regarding AI-based tools and technologies.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Therapeutic applications
  • 1.1.2. Clinical trial phase
  • 1.1.3. End use
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapeutic applications outlook
  • 2.2.2. Clinical trial phase outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. AI-Based Clinical Trials Solution Providers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape
  • 3.3.3. COVID-19 Impact
• 3.4. Case Studies

Chapter 4. AI-Based Clinical Trials Solution Providers Market: Therapeutic Applications Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Therapeutic Applications Movement & Market Share Analysis, 2023 & 2030
• 4.3. Global AI-Based Clinical Trials Solution Providers Market by Therapeutic Applications Outlook
• 4.4. Oncology
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.5. CVD
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million) CVD
• 4.6. Neurological Diseases or Conditions
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.7. Metabolic Diseases
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.8. Infectious Diseases
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. AI-Based Clinical Trials Solution Providers Market: Clinical Trial Phase Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Clinical Trial Phase Movement & Market Share Analysis, 2023 & 2030
• 5.3. Global AI-Based Clinical Trials Solution Providers Market by Clinical Trial Phase Outlook
• 5.4. Phase-I
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.5. Phase-II
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 5.6. Phase-III
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. AI-Based Clinical Trials Solution Providers Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. End Use Movement & Market Share Analysis, 2023 & 2030
• 6.3. Global AI-Based Clinical Trials Solution Providers Market by End Use Outlook
• 6.4. Pharmaceutical Companies
  • 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.5. Academia
  • 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. AI-Based Clinical Trials Solution Providers Market: Regional Estimates & Trend Analysis, By Therapeutic Applications, By Clinical Trial Phase, By End Use

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share/position analysis, 2023
• 8.4. Company Profiles
  • 8.4.1. Unlearn.ai, Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Technology Type benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Saama
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Technology Type benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Antidote Technologies, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Technology Type benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Phesi
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Technology Type benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Deep6.ai
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Technology Type benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Innoplexus
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Technology Type benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Mendel Health Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Technology Type benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Intelligencia AI
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Technology Type benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Median Technologies
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Technology Type benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. SymphonyAI
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Technology Type benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. BioAge Labs, Inc.
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Technology Type benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. AiCure
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Technology Type benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Consilx
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Technology Type benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. DeepLens.AI
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Technology Type benchmarking
    • 8.4.14.4. Strategic initiatives
  • 8.4.15. HaloHealth
    • 8.4.15.1. Company overview
    • 8.4.15.2. Financial performance
    • 8.4.15.3. Technology Type benchmarking
    • 8.4.15.4. Strategic initiatives
  • 8.4.16. PHARMASEAL
    • 8.4.16.1. Company overview
    • 8.4.16.2. Financial performance
    • 8.4.16.3. Technology Type benchmarking
    • 8.4.16.4. Strategic initiatives
  • 8.4.17. Ardigen
    • 8.4.17.1. Company overview
    • 8.4.17.2. Financial performance
    • 8.4.17.3. Technology Type benchmarking
    • 8.4.17.4. Strategic initiatives
  • 8.4.18. Trials.ai
    • 8.4.18.1. Company overview
    • 8.4.18.2. Financial performance
    • 8.4.18.3. Technology Type benchmarking
    • 8.4.18.4. Strategic initiatives
  • 8.4.19. Koneksa Health
    • 8.4.19.1. Company overview
    • 8.4.19.2. Financial performance
    • 8.4.19.3. Technology Type benchmarking
    • 8.4.19.4. Strategic initiatives
  • 8.4.20. Euretos
    • 8.4.20.1. Company overview
    • 8.4.20.2. Financial performance
    • 8.4.20.3. Technology Type benchmarking
    • 8.4.20.4. Strategic initiatives
  • 8.4.21. BioSymetrics, Inc.
    • 8.4.21.1. Company overview
    • 8.4.21.2. Financial performance
    • 8.4.21.3. Technology Type benchmarking
    • 8.4.21.4. Strategic initiatives
  • 8.4.22. Verily (Google LLC)
    • 8.4.22.1. Company overview
    • 8.4.22.2. Financial performance
    • 8.4.22.3. Technology Type benchmarking
    • 8.4.22.4. Strategic initiatives
  • 8.4.23. Aitia
    • 8.4.23.1. Company overview
    • 8.4.23.2. Financial performance
    • 8.4.23.3. Technology Type benchmarking
    • 8.4.23.4. Strategic initiatives
  • 8.4.24. IBM
    • 8.4.24.1. Company overview
    • 8.4.24.2. Financial performance
    • 8.4.24.3. Technology Type benchmarking
    • 8.4.24.4. Strategic initiatives
  • 8.4.25. Exscientia
    • 8.4.25.1. Company overview
    • 8.4.25.2. Financial performance
    • 8.4.25.3. Technology Type benchmarking
    • 8.4.25.4. Strategic initiatives